Boston Scientific (NYSE: BSX) reported Q3 EPS of $0.63, $0.04 better than the analyst estimate of $0.59. Revenue for the quarter came in at $4.21 billion versus the consensus estimate of $4.04 billion.

GUIDANCE:

Boston Scientific sees Q4 2024 EPS of $0.64-$0.66, versus the consensus of $0.64.

Boston Scientific sees FY2024 EPS of $2.45-$2.47, versus the consensus of $2.41.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.